OR WAIT null SECS
The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.
July 09, 2025
Article
Findings highlight the ongoing burden of generalized pustular psoriasis and suggest patients may benefit from targeted biologic therapies like the FDA-approved spesolimab.
In ARRECTOR, patients reported symptom relief and improved quality of life as early as week 2, with strong tolerability and safety through week 8.
Based on reduced FOXP3+ expression in patients, investigators have drawn a strong correlation between MetS due to psoriasis and immune dysregulation.
July 08, 2025
Findings suggest pediatric patients with guttate or inverse psoriasis may warrant evaluation for pharyngeal or anogenital bacterial infections.
Overall, older treatment strategies such as methotrexate and phototherapy still led the way for cost-effectiveness.
July 01, 2025
This FDA news recap highlights some of the most notable approvals and actions by the organization in dermatology during Q2 2025.
June 30, 2025
In our recap for Q2 in dermatology, we spotlight clinical trial findings, recent updates, and advancements in different disease states.
June 29, 2025
In the BE BRIGHT trial presented at SDPA 2025, patients receiving continuous bimekizumab therapy maintained high PASI 90 and PASI 100 response rates over 5 years.
At SDPA 2025, Gordon presented on the future of dermatology, discussing current drugs being evaluated for atopic dermatitis, psoriasis, and hidradenitis suppurativa.